{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T01:45:03Z","timestamp":1795139103924,"version":"4.10.3"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To evaluate the cost effectiveness of various preeclampsia screening and aspirin prophylaxis strategies, including a strategy based on biomarker and ultrasound measures.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>We designed a decision analysis to compare preeclampsia-related costs and effects of four strategies for aspirin use in pregnancy initiated before 16 weeks of gestation to prevent preeclampsia. The four strategies were: 1) no aspirin use, 2) biomarker and ultrasound measure\u2013predicated use, 3) use based on the U.S. Preventive Services Task Force guidelines, and 4) universal aspirin use. Our outcomes were preeclampsia-related costs and number of cases per 100,000 pregnant women. Using a threshold of $90,843 per case of preeclampsia, one-way, two-way, and Monte-Carlo sensitivity analyses incorporating varying probabilities of risk reduction due to aspirin use, aspirin-related side effects, and costs were performed to identify ranges at which costs and risks of aspirin-related complications shifted the preferred strategy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>Compared with universal aspirin administration, the use of U.S. Preventive Services Task Force guidelines is associated with $8,011,725 higher health care costs and 346 additional cases of preeclampsia per 100,000 pregnant women; biomarker and ultrasound screening is associated with an additional $19,216,551 and 308 additional cases. Similarly, no aspirin use is associated with an increased cost of $18,750,381 and 762 additional cases. Thus, universal aspirin use dominated all three other strategies. In a Monte Carlo simulation of 10,000 pregnant women, universal aspirin was the preferred strategy in 91% of simulations. The U.S. Preventive Task Force screen was preferred in 8.5% of simulations, and biomarker and ultrasound screening and no aspirin were preferred in 0% and 0.5% of simulations, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Over a broad range of assumptions, universal aspirin administration is associated with fewer cases of preeclampsia and fewer costs relative to no aspirin administration and aspirin administration based on serum and ultrasound measures or clinical risk factors.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000003413","type":"journal-article","created":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T22:57:33Z","timestamp":1565391453000},"page":"537-544","source":"Crossref","is-referenced-by-count":68,"title":["Strategies for Prescribing Aspirin to Prevent Preeclampsia"],"prefix":"10.1097","volume":"134","author":[{"given":"Divya","family":"Mallampati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Grobman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwight J.","family":"Rouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika F.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230711","doi-asserted-by":"crossref","first-page":"f6564","DOI":"10.1136\/bmj.f6564","article-title":"Pre-eclampsia rates in the United States, 1980\u20132010: age-period-cohort analysis","volume":"347","author":"Ananth","year":"2013","journal-title":"BMJ"},{"key":"R2-20230711","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/ajh.2008.20","article-title":"Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987\u20132004","volume":"21","author":"Wallis","year":"2008","journal-title":"Am J Hypertens"},{"key":"R3-20230711","doi-asserted-by":"crossref","first-page":"503.e1","DOI":"10.1016\/j.ajog.2011.02.020","article-title":"Supplementation with vitamins C and E during pregnancy for the prevention of preeclampsia and other adverse maternal and perinatal outcomes: a systematic review and metaanalysis","volume":"204","author":"Conde-Agudelo","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"R4-20230711","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1056\/NEJM199707103370201","article-title":"Trial of calcium to prevent preeclampsia","volume":"337","author":"Levine","year":"1997","journal-title":"N Engl J Med"},{"key":"R5-20230711","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/AOG.0b013e31827d8ad5","article-title":"Pravastatin for the prevention of preeclampsia in high-risk pregnant women","volume":"121","author":"Costantine","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R6-20230711","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1172\/JCI89031","article-title":"Early pregnancy vitamin D status and risk of preeclampsia","volume":"126","author":"Mirzakhani","year":"2016","journal-title":"J Clin Invest"},{"key":"R7-20230711","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1007\/s40265-017-0823-0","article-title":"Aspirin for prevention of preeclampsia","volume":"77","author":"Atallah","year":"2017","journal-title":"Drugs"},{"key":"R8-20230711","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(07)60712-0","article-title":"Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data","volume":"369","author":"Askie","year":"2007","journal-title":"Lancet"},{"key":"R9-20230711","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/AOG.0b013e3181e9322a","article-title":"Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis","volume":"116","author":"Bujold","year":"2010","journal-title":"Obstet Gynecol"},{"key":"R10-20230711","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajog.2016.09.076","article-title":"The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis","volume":"216","author":"Roberge","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"R11-20230711","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/1471-0528.12170","article-title":"Initiation of aspirin in early gestation for the prevention of pre-eclampsia","volume":"120","author":"Roberge","year":"2013","journal-title":"BJOG"},{"key":"R12-20230711","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/jch.12541","article-title":"Low-dose aspirin for preventing preeclampsia and its complications: a meta-analysis","volume":"17","author":"Xu","year":"2015","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R13-20230711","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1097\/AOG.0000000000002708","article-title":"Low-dose aspirin use during pregnancy. ACOG Committee Opinion No. 743. American College of Obstetricians and Gynecologists","volume":"132","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R15-20230711","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/uog.17399","article-title":"Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11\u201313 weeks' gestation","volume":"49","author":"O'Gorman","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"key":"R16-20230711","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/AOG.0000000000001115","article-title":"A cost-benefit analysis of low-dose aspirin prophylaxis for the prevention of preeclampsia in the United States","volume":"126","author":"Werner","year":"2015","journal-title":"Obstet Gynecol"},{"key":"R17-20230711","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia","volume":"377","author":"Rolnik","year":"2017","journal-title":"N Engl J Med"},{"key":"R18-20230711","doi-asserted-by":"crossref","first-page":"103.e1","DOI":"10.1016\/j.ajog.2015.08.034","article-title":"Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11\u201313 weeks gestation","volume":"214","author":"O'Gorman","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"R19-20230711","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1067\/mob.2002.120280","article-title":"Perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparas","volume":"186","author":"Hnat","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"R20-20230711","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/j.semperi.2006.01.008","article-title":"Preeclampsia as a cause of preterm and late preterm (near-term) births","volume":"30","author":"Sibai","year":"2006","journal-title":"Semin Perinatol"},{"key":"R21-20230711","first-page":"24","article-title":"Pregnancy outcomes in healthy nulliparas who developed hypertension. Calcium for Preeclampsia Prevention Study Group","volume":"95","author":"Hauth","year":"2000","journal-title":"Obstet Gynecol"},{"key":"R22-20230711","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.annepidem.2004.12.008","article-title":"The risk of preeclampsia rises with increasing prepregnancy body mass index","volume":"15","author":"Bodnar","year":"2005","journal-title":"Ann Epidemiol"},{"key":"R23-20230711","doi-asserted-by":"crossref","first-page":"585.e1","DOI":"10.1016\/j.ajog.2017.07.038","article-title":"Aspirin for evidence-based preeclampsia prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history","volume":"217","author":"Poon","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"R24-20230711","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/uog.19019","article-title":"ASPRE trial: incidence of preterm pre-eclampsia in patients fulfilling ACOG and NICE criteria according to risk by FMF algorithm","volume":"51","author":"Poon","year":"2018","journal-title":"Ultrasound Obstet Gynecol"},{"key":"R25-20230711","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/uog.18899","article-title":"Early screening and prevention of preterm pre-eclampsia with aspirin: time for clinical implementation","volume":"50","author":"Rolnik","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"key":"R27-20230711","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1542\/peds.2006-2386","article-title":"Cost of hospitalization for preterm and low birth weight infants in the United States","volume":"120","author":"Russell","year":"2007","journal-title":"Pediatrics"},{"key":"R28-20230711","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/pd.2871","article-title":"Economic assessment of screening for pre-eclampsia","volume":"32","author":"Shmueli","year":"2012","journal-title":"Prenat Diagn"},{"key":"R30-20230711","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/uog.19076","article-title":"Cost-effectiveness of first-trimester screening with early preventative use of aspirin in women at high risk of early-onset pre-eclampsia","volume":"53","author":"Ortved","year":"2019","journal-title":"Ultrasound Obstet Gynecol"},{"key":"R31-20230711","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0140-6736(94)92633-6","article-title":"CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group","volume":"343","year":"1994","journal-title":"Lancet"},{"key":"R32-20230711","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJM199803123381101","article-title":"Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units","volume":"338","author":"Caritis","year":"1998","journal-title":"N Engl J Med"},{"key":"R33-20230711","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1471-0528.1998.tb10088.x","article-title":"Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications","volume":"105","author":"Rotchell","year":"1998","journal-title":"Br J Obstet Gynaecol"},{"key":"R34-20230711","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1053\/j.gastro.2014.06.007","article-title":"Risk of upper gastrointestinal bleeding from different drug combinations","volume":"147","author":"Masclee","year":"2014","journal-title":"Gastroenterology"},{"key":"R35-20230711","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1056\/NEJMra1712125","article-title":"Aspirin-exacerbated respiratory disease","volume":"379","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"R36-20230711","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ajog.2017.04.032","article-title":"Short-term costs of preeclampsia to the United States health care system","volume":"217","author":"Stevens","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"R37-20230711","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1161\/HYPERTENSIONAHA.118.11718","article-title":"Preeclampsia prevention using routine versus screening test-indicated aspirin in low-risk women","volume":"72","author":"Mone","year":"2018","journal-title":"Hypertension"},{"key":"R38-20230711","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.preghy.2016.08.232","article-title":"Aspirin adherence during high-risk pregnancies, a questionnaire study","volume":"6","author":"Abheiden","year":"2016","journal-title":"Pregnancy Hypertens"},{"key":"R39-20230711","doi-asserted-by":"crossref","first-page":"e022056","DOI":"10.1136\/bmjopen-2018-022056","article-title":"Trial of feasibility and acceptability of routine low-dose aspirin versus early screening test indicated aspirin for pre-eclampsia prevention (TEST study): a multicentre randomised controlled trial","volume":"8","author":"Mone","year":"2018","journal-title":"BMJ Open"},{"key":"R40-20230711","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/AOG.0000000000003167","article-title":"A nudge toward universal aspirin for preeclampsia prevention","volume":"133","author":"Ayala","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R41-20230711","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1001\/jama.1990.03440210067034","article-title":"Quality-adjusted life-years. Ethical implications for physicians and policymakers","volume":"263","author":"La Puma","year":"1990","journal-title":"JAMA"},{"key":"R42-20230711","doi-asserted-by":"crossref","first-page":"514.e1","DOI":"10.1016\/j.ajog.2014.04.018","article-title":"Prediction of preeclampsia utilizing the first trimester screening examination","volume":"211","author":"Baschat","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"R43-20230711","doi-asserted-by":"crossref","first-page":"377.e1","DOI":"10.1016\/j.ajog.2014.03.026","article-title":"Population-based biomarker screening and the development of severe preeclampsia in California","volume":"211","author":"Tache","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"R44-20230711","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/uog.12421","article-title":"Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis","volume":"41","author":"Roberge","year":"2013","journal-title":"Ultrasound Obstet Gynecol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000003413","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T19:58:11Z","timestamp":1689105491000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000003413"}},"subtitle":["A Cost-Effectiveness Analysis"],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000003413","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}